# SonoMotion

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sonomotion

- Industry: Medical Devices & Equipment
- Headquarters: San Mateo, US
- Website: www.sonomotion.com
- Total disclosed funding: $15M
- Latest round: Series B (Nov 12, 2019)
- Investors on record: 3

## About

SonoMotion Inc. develops non-invasive ultrasound solutions for kidney stone treatment, utilizing innovative technologies to enhance patient care and streamline medical procedures.Founded in 2014, SonoMotion Inc. is headquartered in San Mateo, US. The company specializes in innovative ultrasound-based medical solutions for kidney stone management. Co-founded by Bryan Cunitz and Oren Levy, SonoMotion has successfully completed 3 funding deals, with the most recent being a Series C round in November 2022, raising USD 12.4 mn from investors including Advanced MedTech Holdings and SolarCity Corporation.SonoMotion specializes in innovative non-invasive solutions for kidney stone treatment, primarily through its core products, Break Wave™ and Stone Clear™. Break Wave™ employs low-pressure ultrasound waves to fragment kidney stones into smaller pieces, allowing for treatment in an office setting without the need for significant anesthesia, thus catering to fully awake patients. Stone Clear™ therapy is designed to reposition residual fragments after lithotripsy, facilitating natural passage of stones within a 15-minute procedure. The company targets over three million patients annually in the United States who seek treatment for kidney stones, as well as healthcare providers and institutions looking to enhance patient care. SonoMotion's products are primarily marketed in the United States, with potential expansion into other international markets as regulatory approvals are secured.SonoMotion's revenue model is predicated on the sale of its proprietary medical devices, Break Wave™ and Stone Clear™, to healthcare facilities, including hospitals and outpatient clinics. Transactions typically occur through direct sales channels, where healthcare providers purchase the devices for use in their practices. The company also engages in partnerships with medical institutions for clinical trials and product validation, enhancing the credibility and adoption of its technologies. While specific pricing structures have not been disclosed, the commercialization of these devices is aimed at improving patient outcomes while providing healthcare providers with innovative, efficient treatment options for kidney stone management.In November 2022, SonoMotion Inc. raised USD 12.4 million in Series C funding co-led by new investor SolarCity and returning investor Advanced MedTech Holdings. The company will utilize this funding to advance the development of its novel Break Wave™ and Stone Clear™ ultrasound solutions in the first half of 2023. SonoMotion plans to further expand its market presence, targeting new geographic regions and healthcare markets as regulatory approvals are obtained.

## Funding rounds

- Series B, Nov 12, 2019, $10M — BioVentures Investors, MedVenture Partners, Advanced MedTech Holdings
- Series A, Apr 7, 2017, $4.6M — BioVentures Investors, MedVenture Partners

## Investors

- BioVentures Investors (https://capitalatlas.ai/funds/bioventures-investors) — Series A, Series B
- MedVenture Partners (https://capitalatlas.ai/funds/medventure-partners) — Series A, Series B
- Advanced MedTech Holdings — Series B